BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.
BEAT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Biotelemetry Inc. To summarize, we found that Biotelemetry Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3114.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for BEAT, they are:
In the past 4.02 years, Biotelemetry Inc has a compound free cash flow growth rate of 1.64%; that's higher than 95.47% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet suggests that 12% of the company's capital is sourced from debt; this is greater than only 23.02% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BEAT, try SUPN, MNK, ACHC, HZNP, and LNTH.